platoseedplatoseed
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.
Entelexo is developing a new class of exosome-based therapeutics to address autoimmune diseases, using a proprietary engineering platform to create and optimize multi-target exosome treatments. They focus on rapid prototyping, data-driven patient patterns, and multi-cell targeting to match the complexities of autoimmune conditions.
The company engineered exosomes to deliver messages to multiple, specific diseased cell types simultaneously using a rational engineering platform that rapidly creates and fine-tunes indication-specific exosome therapies. They de-risk candidates with human cell assays, pursue rapid prototyping, and leverage patient-focused data patterns to optimize product efficacy, progressing from POC/testing through IND-enabling studies and patent prosecution.
Who it’s for: Biotech investors, pharmaceutical partners, and autoimmune disease therapeutic developers seeking novel exosome-based approaches and multi-target cell communication strategies.
Founding/early-stage with YC activity, pre-seed and patent activity, IND-enabling studies planned, several milestones and showcases listed
Dr. Riazifar has worked on stem cells over a decade and on exosomes a subclass of stem cell derived extracellular vesicles since 2012. During his Ph.D studies at the Stem Cell Research Center at the University of California Irvine, he pioneered a cell-free exosome-based approach to treat Multiple Sclerosis. At City of Hope, he was part of a clinical translation team initiating the world’s first clinical trial using stem cell exosomes for the treatment of type I diabetes.
Multidisciplinary engineer with diverse experience in cellular biology, electrical engineering, automotive, and more. To quote Einstein, I am "passionately curious" regarding just about everything.
MSE in Biomedical Engineering from University of Michigan, Class of 2018 Co-Founder and CTO at Entelexo Biotherapeutics.
Potent, durable, and redosable non-viral genetic medicines
